- Home
- CVR vs ENLV Comparison
CVR vs ENLV Comparison
Compare CVR & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVR | ENLV |
|---|---|---|
| Founded | 1920 | 2005 |
| Country | United States | Israel |
| Employees | N/A | 34 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 10.4M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CVR | ENLV |
|---|---|---|
| Price | $10.05 | $0.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 3.9K | ★ 377.9K |
| Earning Date | 05-12-2026 | 05-29-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $27,890,260.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.35 | N/A |
| 52 Week Low | $8.50 | $0.43 |
| 52 Week High | $15.00 | $7.64 |
Technical Indicators
Market Signals| Indicator | CVR | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 21.85 |
| Support Level | $9.62 | $0.43 |
| Resistance Level | $10.43 | $1.26 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 55.68 | 1.42 |
Price Performance
Historical ComparisonAbout CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.